The U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) has announced plans to replace its 2021 rule governing Premarket Tobacco Product Applications (PMTAs) for electronic nicotine delivery systems (ENDS) and nicotine pouches. The agency states the current rule requires updates to reflect legal developments and improve regulatory clarity.

Executive summary

The FDA is undertaking rulemaking to supersede its 2021 PMTA framework, which governs authorization pathways for vapes, nicotine pouches, and other ENDS. The move follows sustained legal challenges, including a lawsuit by Altria, and conflicting court interpretations that have complicated enforcement and product review timelines. No formal proposal or implementation date has been released.

What happened

On October 11, 2026, the FDA CTP confirmed it is drafting a new rule to replace the 2021 PMTA regulation (86 FR 24382). The announcement came amid ongoing litigation where Altria challenged the FDA’s denial of PMTA applications for certain nicotine pouch products, arguing the agency exceeded its statutory authority. Federal courts have issued mixed rulings, with some vacating FDA denials and remanding for reconsideration, creating uncertainty in the product authorization process.

Why it matters

The 2021 PMTA rule established critical procedures for submitting, reviewing, and authorizing ENDS and nicotine pouch products. Its replacement signals the FDA’s acknowledgment that the current framework may not withstand judicial scrutiny or adequately address product class differences. Operators face potential delays in pending applications and uncertainty about future submission requirements.

Regulatory signal: The FDA’s rulemaking effort reflects direct pressure from judicial rulings that have questioned the agency’s PMTA execution under the Tobacco Control Act.

Market impact

Over 1,000 PMTA applications for ENDS and nicotine pouches remain pending or under review. A rule change could reset timelines, require resubmissions, or alter data expectations for toxicology, abuse potential, and youth access studies. Smaller manufacturers may face disproportionate burdens if new requirements increase testing complexity or documentation volume.

Regulatory impact

The FDA intends to align the new rule with recent court guidance on statutory interpretation, particularly regarding the agency’s authority to consider post-market youth impact and product modification rules. The update may also clarify distinctions between ENDS, nicotine pouches, and other non-combustible products under Chapter IX of the Tobacco Control Act.

Market impact: Pending PMTA applicants should anticipate potential revisions to submission guidelines, which could affect product launch planning and investment timelines.

Who is affected

  • Manufacturers and importers of ENDS and nicotine pouches with pending or planned PMTA submissions
  • Retailers and distributors reliant on authorized products for inventory stability
  • Testing laboratories and consulting firms supporting PMTA preparation
  • Public health organizations monitoring product authorization outcomes

Dawsen Take

The FDA’s decision to replace the 2021 PMTA rule is a reactive but necessary step to stabilize the ENDS regulatory pathway amid legal volatility. While intended to improve durability, the process risks introducing further uncertainty during an already protracted authorization environment. Operators should treat the current rule as operative until a final replacement is issued, but prepare for evolving expectations.

What to watch

  • Publication of an advance notice of proposed rulemaking (ANPRM) or proposed rule in the Federal Register
  • Specific changes to data requirements, particularly for nicotine pouch products
  • Timeline for public comment and final rule issuance
  • Impact on pending applications and potential for resubmission requirements
  • Any alignment with concurrent FDA efforts on synthetic nicotine or flavored product policies

For more daily vaping news, check out dawsenai.com

Original source: FDA moves to replace its 2021 PMTA rule

For more daily vaping news, check out dawsenai.com.

Share this post

Written by

Comments

OXVA 发布 ABT:全球首款智能液位检测技术,防止干吸

OXVA 发布 ABT:全球首款智能液位检测技术,防止干吸

By DAWSEN AI • 4 min read
宾夕法尼亚州开始执行ENDS目录销售限制

宾夕法尼亚州开始执行ENDS目录销售限制

By DAWSEN AI • 3 min read
法国推进代际烟草禁令

法国推进代际烟草禁令

By DAWSEN AI • 4 min read